Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
Editas Medicine priced an underwritten public offering of 55.6 million shares and accompanying warrants at a combined price of $2.25 per unit. The initial share sale generates approximately $125 million in gross proceeds, with an additional $194.4 million available if all warrants are exercised at $3.50.
Key figures
- Deal Value Usd
- 125000000
- Offering Price
- 2.25
- Shares Offered
- 55555556
- Warrant proceeds
- 194400000
- Warrant exercise price
- 3.5
- Warrant expiration trigger
- Phase 1 clinical data for EDIT-401 showing >80% LDL reduction in 3+ patients
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.